Granules India and Ajinomoto OmniChem create jv in India

Published: 18-Jul-2011
Manufacturing Ingredients Finance Pharmaceutical

Granules OmniChem will operate an API and intermediates facility in Vishakhapatnam, Andhra Pradesh

Belgian chemicals company Ajinomoto OmniChem and Indian pharmaceuticals manufacturer Granules India have formed a 50:50 joint venture to produce active pharmaceutical ingredients (APIs) and intermediates for third parties.

The new company, Granules-OmniChem, will build a US$20m plant in the Pharmacity SEZ zone in Vishakhapatnam, Andhra Pradesh, initially to manufacture high-value, low-volume APIs and intermediates.

Construction of the facility will start in November and should be completed towards the end of 2012.

The jv aims to capitalise on demand from pharmaceutical firms which are outsourcing their manufacturing needs at a time when the industry is focused on the US$234bn generics market. More than 80% of API production is for the generics market.

Granules-Omnichem will focus on producing APIs and intermediates for existing customers of both partners and in the future manufacture new chemical entities.

‘Our shareholders will benefit since this will enable Granules to diversify its business by offering high value APIs and intermediates which will increase our profitability,’ said Krishna Prasad, managing director of Granules.

Gwin Bompas, managing director of Ajinomoto OmniChem, which employs around 700 people at three sites in Belgium, said the jv would enable the firm to ‘offer access to quality medicine at an affordable price for the market’.

Granules India manufactures finished dosage forms, pharmaceutical intermediates and APIs, which are distributed in more than 50 countries.

See more

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

Read more
The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India

Trending Articles

  1. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
  2. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  3. How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India
Finance

Indian Big Pharma companies buck the global economic trend

India\'s top 25 pharma companies continue to go from strength to strength
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

FUJIFILM Cellular Dynamics opens new iPSC manufacturing facility in US

The new site will serve as the company's headquarters and will increase Fujifilm's capacity for induced pluripotent stem cell development and manufacturing, as demand increases with new approach methods in research
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Subscribe now